Molecular field technology applied to virtual screening and finding the bioactive conformation.

Area of Science:

• Computational chemistry and cheminformatics
• Drug discovery and pharmaceutical sciences

Background:

• High-throughput screening (HTS) in pharmaceutical companies faces bottlenecks and significant compound wastage.
• Virtual screening (VS) offers a solution to streamline the drug discovery process.
• Ligand-based virtual screening (LBVS) is a key strategy within VS.

Purpose of the Study:

• To introduce and evaluate Cresset's ligand-based virtual screening technology utilizing molecular fields.
• To demonstrate the technology's capability in rapidly identifying novel chemotypes.
• To showcase the prediction of bioactive conformation for ligands.

Main Methods:

• Calculation of four molecular fields based on probe atom interactions with ligands.
• Utilizing field similarity to known active ligands for activity prediction.
• Predicting bioactive conformation from 2D structures without target site information.

Main Results:

• Cresset's technology facilitates rapid identification of novel chemotypes by testing only 200-1000 compounds.
• Compounds with similar molecular fields to known actives show a high probability of similar biological activity.
• Field similarity enables prediction of bioactive conformations for diverse ligands.

Conclusions:

• Ligand-based virtual screening with molecular fields is an effective method to reduce HTS bottlenecks and compound wastage.
• The technology enables efficient discovery of novel chemical structures with potential therapeutic value.
• Predicting bioactive conformation using field similarity is a valuable tool in early-stage drug design.